Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Zenith Capital (OTC:ZHCLF) Stock in Focus: The Next Catalyst to Watch

Zenith Capital Corporation (OTC:ZHCLF) sits at the speculative fringe of the market, a sub-dollar, thinly traded over-the-counter stock whose five-letter 'F' ticker denotes a foreign issuer. The shares showed no change at last closing, and the headline frames the story around a potential future …

Nitish Kishor | 14 September 2026

Tradewinds Universal (OTC:TRWD) Stock Gains Ground: Is It Quietly Building Momentum?

Tradewinds Universal (OTC:TRWD) is about as far from a conventional health-or-technology story as aStock Screeneris likely to surface: a sub-penny, over-the-counter name in the middle of a dramatic reinvention. Shares closed up 8.33% at $0.01 at last closing, but at a fraction of a …

Nitish Kishor | 14 September 2026

Turn Therapeutics (NASDAQ:TTRX) Falls: What Investors Should Watch

Few micro-cap biotechs have assembled aLeadershiproster quite like Turn Therapeutics Inc (NASDAQ:TTRX). The clinical-stage skin-disease specialist has drawn attention less for a single product milestone than for the marquee names now attached to its research effort, and its shares closed down 5.16% at $12.69 …

Nitish Kishor | 14 September 2026

Whitehawk Therapeutics (NASDAQ: WHWK) Records September 9 Award of 76,080 Derivatives

Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) awarded insider Iyengar Vijay K 76,080 derivative securities on 9 September 2026. The resulting position was reported at 76,080 derivative securities.

Vinay Lochav | 14 September 2026

Vogenx (NASDAQ:VOGX) Surges: Is This a Turning Point or a Reset?

Barely a month after pricing its market debut, Vogenx, Inc. (NASDAQ: VOGX) surged in the September 2026 session, closing up 9.54% at $32.71 at last closing. The metabolic-disease developer has been one of a wave of new biotech listings this year, and its early …

Nitish Kishor | 14 September 2026

Yarrow Bioscience Prospectus Covers 25,781,240 Warrant-Linked Shares (NASDAQ: YARW)

Yarrow Bioscience, Inc. (NASDAQ: YARW) is offering common stock and pre-funded warrants, with up to $50.0 million of common stock available for sale under an amended sales agreement. The securities package gives some investors a warrant alternative priced at $0.0001 below the public offering …

Vinay Lochav | 14 September 2026

Mobia Medical (NASDAQ:MOBI) Stock Eases Back: Key Levels and Catalysts to Watch

Commercial-stageMedTechnames rarely blend a fresh IPO, real revenue and clinical validation, but Mobia Medical is doing exactly that. Shares closed down 2.34% at $10.01 at last closing, a modest dip for a company that came public in May 2026 and has since posted brisk …

Nitish Kishor | 14 September 2026

MapLight Therapeutics (NASDAQ:MPLT) Falls: What's Pressuring the Stock?

MapLight Therapeutics, Inc. (NASDAQ:MPLT) has been one of the more closely tracked neuroscience names to reach public markets in the past year, and its shares closed down 5.69% at $13.00 at last closing. After debuting in late 2025, the stock has swung across a …

Nitish Kishor | 14 September 2026

Odyssey Therapeutics (NASDAQ:ODTX) Stock Climbs: What's Fueling the Move?

A gain in Odyssey Therapeutics, Inc (NASDAQ:ODTX) has put the clinical-stage biopharmaceutical company back in the spotlight only months after its market debut. Shares closed up 4.19% at $24.63 at last closing, a move large enough to draw notice but not obviously tied to …

Nitish Kishor | 14 September 2026

Senti Biosciences Gets $2.5M Post-Merger Equity Commitment (NASDAQ: SNTI)

Celadon Partners SPV 24, Celadon Partners, LLC and CPIF II-7 Limited are reported as beneficial owners of 25,748,890.00 Senti shares, equal to 54.6%, under an activist position. A related entity has committed $2,500,000 to newly issued shares, with proceeds intended to support Senti’sBusinessafter the …

Vinay Lochav | 14 September 2026
Support

Hi! How can we help you today?

Loading…